Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).

Bibliographic Details
Main Authors:	Glynne-Jones, R, Sebag-Montefiore, D, Samuel, L, Falk, S, Maughan, T, McDonald, A
Format:	Conference item
Published:	2005

Preliminary phase IISOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (IRT) in patients (pts) with locally advanced rectal cancer (LARC).
by: Glynne-Jones, R, et al.
Published: (2004)

A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study.
by: Sebag-Montefiore, D, et al.
Published: (2005)

A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study.
by: Glynne-Jones, R, et al.
Published: (2007)

Capecitabine (X) and oxaliplatin (O) combination chemotherapy in patients (pts) with advanced gall bladder or biliary tract cancer: A phase II study
by: Evans, T, et al.
Published: (2006)

Preoperative chemoradiotherapy with capecitabine and triweekly oxaliplatin versus capecitabine monotherapy for locally advanced rectal cancer: a propensity-score matched study
by: Anchuan Li, et al.
Published: (2022-07-01)

Neoadjuvant Capecitabine and Oxaliplatin Before Concurrent Capecitabine and Radiation in Locally Advanced Rectal Cancers: Experience of a Cancer Hospital in Pakistan
by: Muhammad Atif Mansha, et al.
Published: (2021-12-01)

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma
by: Mukherjee, S, et al.
Published: (2017)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial.
by: Madi, A, et al.
Published: (2012)

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: The MRC COIN trial
by: Madi, A, et al.
Published: (2012)

Induction chemotherapy with capecitabine and oxaliplatin followed by chemoradiotherapy before surgery in patients with locally advanced rectal cancer
by: Aly Mohammed Azmy, et al.
Published: (2022-01-01)

Prospective clinical study of capecitabine plus oxaliplatin concurrent chemoradiotherapy after radical resection of rectal cancer
by: Wanghua Chen, et al.
Published: (2018-08-01)

A phase II study of neoadjuvant capecitabine, oxaliplatin, and irinotecan (XELOXIRI) in patients with locally advanced rectal cancer
by: Chu Matsuda, et al.
Published: (2023-01-01)

Economic comparison of capecitabine + oxaliplatin and 5-fluorouracil + oxaliplatin in the adjuvant treatment of colon cancer
by: Colombo GL., et al.
Published: (2012-03-01)

NEOSCOPE: a randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine or paclitaxel/carboplatin based chemoradiation as pre-operative regimen for resectable oesophageal adenocarcinoma.
by: Mukherjee, S, et al.
Published: (2015)

Cost-effectiveness analysis of capecitabine monotherapy versus capecitabine plus oxaliplatin in elderly patients with advanced gastric cancer.
by: Jingyuan Peng, et al.
Published: (2018-01-01)

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).
by: Diaz-Rubio, E, et al.
Published: (2004)

Tryptophan Catabolism and Response to Therapy in Locally Advanced Rectal Cancer (LARC) Patients
by: Sara Crotti, et al.
Published: (2020-10-01)

The Larc reports /
by: 10713 Library Automation Research and Consulting Association
Published: ([19-)

Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study
by: Xin Yu, et al.
Published: (2018-05-01)

Analysis of capecitabine plus oxaliplatin (xelox) combination in the management of metastatic colorectal cancer compare with fluorouracil and oxaliplatin combination (folfox)
by: Isnatin Miladiyah
Published: (2016-12-01)

Acute mania due to capecitabine and oxaliplatin in a patient with metastatic colorectal cancer
by: Parikshit Padhi
Published: (2023-03-01)

First reported case of ANCA-associated vasculitis induced by oxaliplatin, capecitabine, and trastuzumab
by: Bengang Huo, et al.
Published: (2023-12-01)

Toxicity, tolerability & compliance of concurrent capecitabine or 5-fluorouracil in the radical management of anal cancer with single-dose mitomycin-C and intensity modulated radiation therapy: evaluation of a national cohort
by: Jones, C, et al.
Published: (2018)

BACCHUS: A randomised non-comparative phase II study of neoadjuvant chemotherapy (NACT) in patients with locally advanced rectal cancer (LARC)
by: R. Glynne-Jones, et al.
Published: (2018-09-01)

Relapsed urachal carcinoma responding to first‐line chemotherapy with capecitabine‐oxaliplatin plus bevacizumab
by: Akihiko Hatano, et al.
Published: (2023-11-01)

Real-world efficacy and safety of capecitabine with oxaliplatin in patients with advanced adenocarcinoma of the ampulla of Vater
by: Seunghwan Lee, et al.
Published: (2024-05-01)

Cost-Effectiveness Analysis of Capecitabine Plus Oxaliplatin Versus Gemcitabine Plus Oxaliplatin as First-Line Therapy for Advanced Biliary Tract Cancers
by: Ruijia Chen, et al.
Published: (2022-07-01)

Efficacy after preoperative capecitabine and oxaliplatin (XELOX) versus docetaxel, oxaliplatin and S1 (DOS) in patients with locally advanced gastric adenocarcinoma: a propensity score matching analysis
by: Yan Wang, et al.
Published: (2018-06-01)

Multidisciplinary approach to the management of capecitabine-associated hand foot syndrome in cancer patients receiving capecitabine plus oxaliplatin and bevacizumab for advanced colorectal cancer
by: Hiroshi Matsuoka, et al.
Published: (2017-02-01)

Capecitabine enhances sensitivity to oxaliplatin in advanced gastric cancer and the effects on patients’ FOXP1 and GGT levels
by: Xinyu Guo, et al.
Published: (2025-01-01)

Capecitabine enhances sensitivity to oxaliplatin in advanced gastric cancer and the effects on patients' FOXP1 and GGT levels
by: Xinyu Guo, et al.
Published: (2024-11-01)

Evaluation of Outcome and Tolerability of Combination Chemotherapy with Capecitabine and Oxaliplatin as First Line Therapy in Advanced Gastric Cancer
by: Mohammad Ali Mashhadi, et al.
Published: (2016-10-01)

The clinical and cost-effectiveness of oxaliplatin and capecitabine for the adjuvant treatment of colon cancer: systematic review and economic evaluation
by: A Pandor, et al.
Published: (2006-11-01)

Bevacizumab Combined With Oxaliplatin/Capecitabine in Patient With Refractory and Recurrent Mucinous Adenocarcinoma of the Appendix: A Case Report
by: Wenzhi Liu, et al.
Published: (2019-02-01)

L’arc et l’escarpin
by: Laurent Jullier
Published: (2015-02-01)

Addition of SHR-1701 to first-line capecitabine and oxaliplatin (XELOX) plus bevacizumab for unresectable metastatic colorectal cancer
by: Miao-Zhen Qiu, et al.
Published: (2024-12-01)

Short-term efficacy and safety of sintilimab combined with oxaliplatin and capecitabine as neoadjuvant therapy for locally advanced gastric cancer
by: ZHANG Shuai, LIU Liangliang, HUANG Di, SHENG Ru, DU Xuetao, LI Shuguang, HU Nan, ZHAO Yifeng
Published: (2025-01-01)

Prolonged administration of the granisetron transdermal delivery system reduces capecitabine plus oxaliplatin regimen induced nausea and vomiting
by: Cong Wang, et al.
Published: (2024-07-01)

Cardiotoxicity induced by capecitabine and oxaliplatin in gastric cancer treatment: a rare case of cardiac arrest and cardiogenic shock
by: Muhammad Umer Riaz Gondal, et al.
Published: (2024-03-01)

Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).

Similar Items

Similar Items